世華科技(688093.SH):公司2022年在生物基材料上已實現大客户認證並量產銷售
格隆匯8月2日丨世華科技(688093.SH)近期在接待機構投資者調研時表示,公司2022年在生物基材料上已實現大客户認證並量產銷售,目前正在持續推進新項目驗證。生物基技術是控碳的關鍵技術,生物基材料契合當下控碳減排的政策,公司看好生物基材料的發展前景。基於當前的市場情況、技術條件以及工藝條件,生物基材料的單位成本相對較高,在原材料提純、性能穩定性上還存在一定技術難點。後期隨着技術的提升、成熟,生物基材料的成本會逐漸降低。生物基材料替代石油基材料需要一定的過程。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.